Lead Product(s) : Zatolmilast
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Shionogi Updates on Zatolmilast for Fragile X Syndrome, Including Study Protocol Changes
Details : BPN14770 (zatolmilast) is an investigational drug that works by PDE4D inhibitor, which is used to promote the maturation of connections between neurons that are impaired in individuals with FXS.
Product Name : BPN14770
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 18, 2024
Lead Product(s) : Zatolmilast
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Emixustat Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Emixustat modulates the visual cycle by inhibiting a critical enzyme of this pathway, retinal pigment epithelium protein 65 (RPE65). The visual cycle is the process by which vitamin A is recycled in the eye; vitamin A is crucial to the visual process.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 23, 2022
Lead Product(s) : Emixustat Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lanadelumab
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TAKHZYRO® (lanadelumab-flyo) Injection is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 12 years of age and older.
Product Name : Takhzyro
Product Type : Antibody
Upfront Cash : Inapplicable
May 10, 2022
Lead Product(s) : Lanadelumab
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Emixustat Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Emixustat modulates visual cycle by inhibiting a critical enzyme of this pathway, retinal pigment epithelium protein 65, in analysis of Phase 3 trial it is determined that emixustat treatment resulted in a 40.8% reduction in lesion progression compared t...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 10, 2022
Lead Product(s) : Emixustat Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pabinafusp Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JR-141 is the first-ever approved enzyme replacement therapy (ERT) in Japan that penetrates the BBB via intravenous administration for the treatment of MPS II. JR-141 is expected to treat not only the systemic symptoms but also the neuronopathic manifest...
Product Name : Izcargo
Product Type : Protein
Upfront Cash : Inapplicable
February 15, 2022
Lead Product(s) : Pabinafusp Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Deramiocel
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Capricor Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Details : CAP-1002 is comprised of human allogeneic cardiosphere-derived cells. Exosomes (extracellular vesicles) secreted by CAP-1002 are thought to be the mechanism of action of CAP-1002 and have been shown to reduce oxidative stress, inflammation, fibrosis.
Product Name : CAP-1002
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
January 25, 2022
Lead Product(s) : Deramiocel
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Capricor Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Pabinafusp Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Takeda Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the terms of the collaboration and license agreement, Takeda will exclusively commercialize JR-141, a recombinant fusion protein of an antibody against the human transferrin receptor and iduronate-2-sulfatase in the U.S. upon completion of the Pha...
Product Name : Izcargo
Product Type : Protein
Upfront Cash : Undisclosed
September 30, 2021
Lead Product(s) : Pabinafusp Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Takeda Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Recombinant Von Willebrand Factor
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In Europe, VEYVONDI is indicated in adults (age 18 and older) with von Willebrand disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or not indicated for the treatment of hemorrhage and treatment/prevention of surgical bleeding.
Product Name : Vonvendi
Product Type : Protein
Upfront Cash : Inapplicable
July 20, 2021
Lead Product(s) : Recombinant Von Willebrand Factor
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Viltolarsen
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
EC Grants Orphan Drug Designation to Nippon Shinyaku's viltolarsen (NS-065/NCNP-01)
Details : The NDA for viltolarsen is also being reviewed under an accelerated approval pathway in the U.S. The clinical study in the US is being conducted by NS Pharma, Inc.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
August 06, 2020
Lead Product(s) : Viltolarsen
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Emixustat Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : This publication supports the rationale for investigating emixustat in the treatment of Stargardt disease and diabetic retinopathy.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 01, 2020
Lead Product(s) : Emixustat Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable